SOPHiA GENETICS Achieves CE-IVD Milestone for Its Solid Tumor Solution for Accurate Cancer Detection

Lausanne, Switzerland (ots/PRNewswire) - SOPHiA GENETICS, global
leader in Data-Driven Medicine, announced today the CE-IVD marking of
its Solid Tumor Solution (STS), a new step in the fight against
cancer. This standardized molecular diagnostic application precisely
detects and characterizes all types of genomic alterations in 42
clinically relevant genes associated with a range of solid tumors
such as lung, colorectal, skin and brain cancers.

Cancer is responsible for an estimated 9.6 million deaths in 2018,
making it the second leading cause of death globally[1]. "As about 1
in 6 deaths is due to cancer nowadays, it is essential to give
patients an early and precise diagnosis. The newly approved CE-IVD
Solid Tumor Solution represents a major advancement in the
personalization of cancer care. It is designed to maximize diagnostic
yield and guide treatment and management decisions," says Gioia
Althoff, Senior Vice President Genomics at SOPHiA GENETICS.

The STS leverages the full power of SOPHiA, the leading technology
of choice for streamlined Data-Driven Medicine applications. In
oncology, SOPHiA helps clinicians with decision support
functionalities based on precision medicine intelligence. It enables
simple, central access to relevant therapeutic, prognostic and
diagnostic databases to determine the actionability and clinical
significance of genomic alterations associated with the cancer type.

The solution has been highly optimized to deliver exceptional
accuracy and precision. It can detect single nucleotide variants
(SNVs), insertions, deletions (Indels) and gene amplification events.
It also identifies microsatellite instability (MSI) status in 6
unique loci associated with colorectal cancer, which is currently
recommended for all patients with this disease.

The CE-IVD marking for STS demonstrates the commitment of SOPHiA
GENETICS in maintaining a firm focus on delivering robust, dependable
and accessible solutions to hospitals all over the world, including
some 920 hospitals to date. With the help of SOPHiA's collective
expertise and global network, healthcare professionals can
confidently adopt standardized Data-Driven Medicine applications as a
part of their routine workflow.

"Personalizing cancer care requires precision in the analysis,
clinical interpretation and reporting. The Solid Tumor Solution by
SOPHiA GENETICSis a quality-approved solution that helped us
streamline the genomic testing workflow and get clinical-grade
performance. With the STS, our lab has access to a comprehensive
solution that accurately detects clinically relevant genomic
alterations associated with solid tumors, accelerating the
clinicians' ability to diagnose patients and deliver the best
treatment options," comments Dr. Jose López, Head of Molecular
Biology Laboratory at the Instituto Valenciano de Oncología (IVO) -
Valencia, Spain.

About SOPHiA GENETICS

Leader in Data-Driven Medicine, SOPHiA GENETICS is a health tech
company which has developed SOPHiA AI, the advanced technology
helping healthcare professionals better diagnose their patients.
SOPHiA GENETICS is democratizing Data-Driven Medicine by enabling the
rapid adoption of genomic and radiomic analysis worldwide, turning
data into actionable clinical insights, and sharing knowledge through
its community. The company's achievements and innovative approach are
recognized by The MIT Technology Review's "50 Smartest Companies
2017".

For media and journalists' inquiries, please contact our Media
Relations Officer Sophie Reymond by either email or telephone:

More info: SOPHiAGENETICS.COM (https://sophiagenetics.com/),
follow @SOPHiAGENETICS (https://twitter.com/SOPHiAGENETICS).

About IVO

The Valencia Oncology Institute Foundation (Instituto Valenciano
de Oncología - IVO) is a private non-profit organization whose assets
and economic resources are used entirely for the fight against
cancer. It is a reference center in cancer treatment in Europe.

[1]Reference:
https://www.who.int/news-room/fact-sheets/detail/cancer

Photo: https://mma.prnewswire.com/media/870015/SOPHiA_GENETICS.jpg

ots Originaltext: Sophia Genetics
Im Internet recherchierbar: http://www.presseportal.de

Contact:
SReymond@sophiagenetics.com or +41-21-694-10-78.

Original-Content von: Sophia Genetics, übermittelt durch news aktuell